Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941088 | 0.98 | KMT2A (0.54) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1983267 | 0.84 | L3MBTL1 (0.51) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11108445 | 0.84 | KMT2A (0.58) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL10292855 | 0.84 | MAPT (0.43) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6689403 | 0.83 | ALDH1A1 (0.46) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL338575 | 0.82 | KMT2A (0.53) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11581341 | 0.82 | ALDH1A1 (0.55) | KMT2AL3MBTL1ALDH1A1HSD17B10MAPT | |
| SCHEMBL6496987 | 0.82 | KMT2A (0.53) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL556208 | 0.82 | KMT2A (0.53) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4593935 | 0.81 | THRA (0.49) | KMT2AL3MBTL1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4471019-A1 | 3-[(BENZO[D][1,3]DIOXOLANE-4-YL)OXY]PROPYLAMINE HYDROCHLORIDE, OPTICAL ISOMER AND CRYSTAL THEREOF, AND PREPARATION METHOD THEREFOR | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023143455-A1 | 3-[(BENZO[D][1,3]DIOXOLANE-4-YL)OXY]PROPYLAMINE HYDROCHLORIDE, OPTICAL ISOMER AND CRYSTAL THEREOF, AND PREPARATION METHOD THEREFOR | 江苏恩华药业股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-105777706-B | A kind of 3- [(benzo [d] [1,3] dioxolanes -4- base)-oxygroup] -3- arylprop aminated compounds and its application | 江苏恩华药业股份有限公司 | 2019-08-23 | — | — | CN | disclosed |
| US-9856236-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2018-01-02 | — | — | US | disclosed |
| US-9290478-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-02-04 | — | — | US | disclosed |
| CN-103370314-B | As the replacement benzo pyrazines derivatives of FGFR kinase inhibitor being used for the treatment of Cancerous disease | ASTEX THERAPEUTICS LTD. (GB) | 2015-10-21 | — | — | CN | disclosed |
| US-9145394-B2 | — | — | 2015-09-29 | — | — | US | disclosed |
| EP-2646432-B1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| CN-103370314-A | Substituted benzopyrazin derivatives as FGFR kinase inhibitors for the treatment of cancer diseases | ASTEX THERAPEUTICS LTD | 2013-10-23 | — | — | CN | disclosed |
| US-5229417-A | Obsessive compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-20 | — | — | US | disclosed |
| US-5225585-A | Antidepressants | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1993-07-06 | — | — | US | disclosed |
| EP-0545425-A1 | 2-(3-Phenylpropyl)hydrazines, intermediates in and a process for the preparation thereof, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-06-09 | — | — | EP | disclosed |
| EP-0540016-A1 | Photosensitive resin and resin composition for lithographic printing | Nippon Paint Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0529842-A2 | Production of fluoxetine and new intermediates | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-03-03 | — | — | EP | disclosed |
| US-5143938-A | PROPANAMINES, THEIR PHARMACOLOGICAL PROPERTIES AND THEIR APPLICATION FOR THERAPEUTIC IN PARTICULAR ANTIDIARRHEAL, PURPOSES | JOUVEINAL S.A. (FR) | 1992-09-01 | — | — | US | disclosed |
| EP-0336753-B1 | IMPROVEMENTS IN OR RELATING TO PROPANAMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0391107-A1 | Benzazepine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| US-4952692-A | Benzazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-08-28 | — | — | US | disclosed |
| EP-0336753-A1 | Improvements in or relating to propanamine derivatives | ELI LILLY AND COMPANY (US) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, ABL1 | HDAC1 2007/4885HDAC6 1167/4885KMT2A 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.